Corcept Therapeutics Incorporated (CORT)

Return on total capital

		Dec 31, 2023	Sep 30, 2023	Jun 30, 2023	Mar 31, 2023	Dec 31, 2022	Sep 30, 2022	Jun 30, 2022	Mar 31, 2022	Dec 31, 2021	Sep 30, 2021	Jun 30, 2021	Mar 31, 2021	Dec 31, 2020	Sep 30, 2020	Jun 30, 2020	Mar 31, 2020	Dec 31, 2019	Sep 30, 2019	Jun 30, 2019	Mar 31, 2019
Earnings before interest and tax (EBIT) (ttm)	US$ in thousands	107,282	98,112	98,869	100,718	112,634	126,799	131,097	131,608	124,477	118,323	106,810	110,129	128,202	132,708	140,993	130,364	111,609	101,491	91,456	87,457
Long-term debt	US$ in thousands	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—
Total stockholders’ equity	US$ in thousands	506,705	461,679	421,614	529,584	501,842	473,364	442,326	407,811	375,806	540,229	522,675	510,802	523,338	489,680	453,698	409,489	371,182	334,376	298,053	285,755
Return on total capital		21.17%	21.25%	23.45%	19.02%	22.44%	26.79%	29.64%	32.27%	33.12%	21.90%	20.44%	21.56%	24.50%	27.10%	31.08%	31.84%	30.07%	30.35%	30.68%	30.61%

December 31, 2023 calculation

Return on total capital = EBIT (ttm) ÷ (Long-term debt + Total stockholders’ equity)
= $107,282K ÷ ($—K + $506,705K)
= 21.17%

Corcept Therapeutics Inc's return on total capital has shown fluctuations over the past eight quarters. The figures have ranged from a high of 32.27% in Q1 2022 to a low of 19.02% in Q1 2023. The company's return on total capital has generally been in the double digits, indicating efficient use of both debt and equity to generate profits. While there was a slight decline in the metric in the most recent quarters, the overall trend suggests that Corcept Therapeutics Inc has been able to effectively generate returns on its total invested capital. This indicates the company's ability to generate earnings relative to the combined capital from debt and equity sources.